Neuroscience

Integrative analytical technology specialist InforSense announced in May the licensing of its workflow-based informatics platforms by the Windber Research Institute (WRI), a biomedical research center looking for cures to genetic and metabolic diseases. The two organizations will work together to develop a production-quality, generic informatics framework for translational medicine to be used by WRI and its clinical collaborators.

A $500,000 grant from the National Science Foundation (NSF) will support the RNA Ontology Consortium, an international team of scientists developing a shared vocabulary and system for discussing RNA structure and function.

Applied Biosystems in mid-March introduced a new plan, the Advanced Gene Expression Service Provider Program (AGESPP), to sell varying combinations of instrumentation, supplies, services, and marketing support in custom-made bundles at discounted prices.

RNAi biopharmaceutical company Alnylam took another step on the road to moving its age-related macular degeneration (AMD) and respiratory syncytial virus (RSV) infection programs closer to clinical trials in late March by naming Dowpharma its manufacturer-of-choice for large-scale quantities of short interfering RNAs (siRNAs).

Metabolon Inc. in early April announced it received a grant from the National Institute of Environmental Health Sciences (NIEHS) for its continued research into the discovery of biomarkers for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease.

Health science heavyweight PerkinElmer and proteomics technology developer Procognia announced in mid-December a co-marketing agreement that combines PE’s Protein Array Workstation and ProScan Array HT with Procognia’s U-c lectin array-based platform to c

Novasite Pharmaceuticals Inc. announced it has received a four-year grant valued at nearly $3.4 million for continued development of its proprietary parallel screening technology for G-Protein Coupled Receptors (GPCRs).